{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:06:18Z","timestamp":1768561578245,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We aimed to assess vaccine-induced humoral immunity and durability in older PWH (\u2265\u200955\u00a0years, n\u2009=\u200926) over 6\u00a0months (post-initial BNT162b2 series). A secondary and exploratory objective was to assess T-cell response and BNT162b2 booster reactogenicity, respectively. Our Visit 1 (3\u00a0weeks post-initial BNT162b2 dose) SARS-CoV-2 humoral immunity results are previously reported; these subjects were recruited for Visit 2 [2\u00a0weeks (+\u20091\u00a0week window) post-second vaccination] and Visit 3 [6\u00a0months (\u00b1\u20092\u00a0week window) post-initial vaccination] in a single-center longitudinal observational study. Twelve participants had paired Visit 2\/3 SARS-CoV-2 Anti-Spike IgG data. At Visit 3, SARS-CoV-2 Anti-Spike IgG testing occurred, and 5 subjects underwent T-cell immune response evaluation. Thereafter, subjects were offered BNT162b2 booster (concurrent day outside our study) per US FDA\/CDC guidance; reactogenicity was assessed. The primary study outcome was presence of detectable Visit 3 SARS-CoV-2 Anti-Spike-1-RBD IgG levels. Secondary and exploratory outcomes were T-cell immune response and BNT162b2 booster reactogenicity, respectively. Wilcoxon signed-rank tests analyzed median SARS-CoV-2 Anti-Spike IgG 6-month trends.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At Visit 3, 26 subjects underwent primary analysis with demographics noted: Median age 61\u00a0years; male n\u2009=\u200916 (62%), female n\u2009=\u200910 (38%); Black n\u2009=\u200913 (50%), White n\u2009=\u200913 (50%). Most subjects (n\u2009=\u200920, 77%) had suppressed HIV viremia on antiretroviral therapy, majority (n\u2009=\u200924, 92%) with CD4\u2009&gt;\u2009200 cells\/\u00b5L. At Visit 3, 26\/26 (100%) had detectable Anti-Spike-1-RBD (\u2265\u20090.8 U\/mL). Among 12 subjects presenting to Visit 2\/3, median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U\/mL at Visit 2, falling to 581.5 U\/mL at Visit 3 (p\u2009=\u20090.0923), with a median 3.305-fold decrease over 6\u00a0months. Among subjects (n\u2009=\u20095) with 6-month T-cell responses measured, all had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4\u2009+\u2009Activation induced marker (AIM)\u2009+\u2009cells. Two had detectable cytokine-secreting CD8 responses, but all had positive CD8\u2009+\u2009AIM\u2009+\u2009cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among older PWH, SARS-CoV-2 Anti-Spike IgG and virus-specific T-cell responses are present 6\u00a0months post-primary BNT162b2 vaccination, and although waning, suggest retention of some degree of long-term protective immunity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07737-0","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:02:58Z","timestamp":1663768978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)"],"prefix":"10.1186","volume":"22","author":[{"given":"Jessica J.","family":"Tuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anousheh","family":"Behnegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehanzeb","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Mutic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ryall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terese","family":"Critch-Gilfillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syim","family":"Salahuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaili","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brinda","family":"Emu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"26","key":"7737_CR1","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa2115624","volume":"385","author":"R Arbel","year":"2021","unstructured":"Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to COVID-19. N Engl J Med. 2021;385(26):2413\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2115624.","journal-title":"N Engl J Med"},{"key":"7737_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.puhe.2021.07.037","volume":"198","author":"K Jab\u0142o\u0144ska","year":"2021","unstructured":"Jab\u0142o\u0144ska K, Aball\u00e9a S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021;198:230\u20137. https:\/\/doi.org\/10.1016\/j.puhe.2021.07.037.","journal-title":"Public Health"},{"issue":"6","key":"7737_CR3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589\u2013603. https:\/\/doi.org\/10.1016\/j.cell.2021.02.030.","journal-title":"Cell"},{"issue":"4","key":"7737_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/jmv.27485","volume":"94","author":"S Falahi","year":"2022","unstructured":"Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: implications for COVID-19 vaccines. J Med Virol. 2022;94(4):1330\u20135. https:\/\/doi.org\/10.1002\/jmv.27485.","journal-title":"J Med Virol"},{"key":"7737_CR5","doi-asserted-by":"publisher","unstructured":"Tuan JJ, Zapata H, Critch-Gilfillan T, et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV [published online ahead of print, 2021 Oct 10]. HIV Med. 2021. https:\/\/doi.org\/10.1111\/hiv.13188","DOI":"10.1111\/hiv.13188"},{"issue":"13","key":"7737_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244\u20136. https:\/\/doi.org\/10.1056\/NEJMc2111462.","journal-title":"N Engl J Med"},{"key":"7737_CR7","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinicalinfo.hiv.gov. August 16, 2021. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/hiv-and-older-person."},{"issue":"1","key":"7737_CR8","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1038\/s41598-022-15378-1","volume":"12","author":"M Gdoura","year":"2022","unstructured":"Gdoura M, Ghaloum FB, Hamida MB, Chamsa W, Triki H, Bahloul C. Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans. Sci Rep. 2022;12(1):11298. https:\/\/doi.org\/10.1038\/s41598-022-15378-1.","journal-title":"Sci Rep"},{"issue":"1","key":"7737_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41421-022-00373-7","volume":"8","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8(1):10. https:\/\/doi.org\/10.1038\/s41421-022-00373-7.","journal-title":"Cell Discov."},{"issue":"7901","key":"7737_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","volume":"603","author":"R Keeton","year":"2022","unstructured":"Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize omicron. Nature. 2022;603(7901):488\u201392. https:\/\/doi.org\/10.1038\/s41586-022-04460-3.","journal-title":"Nature"},{"issue":"20","key":"7737_CR11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira Jr","year":"2022","unstructured":"Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med. 2022;386(20):1910\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2200674.","journal-title":"N Engl J Med"},{"issue":"4","key":"7737_CR12","doi-asserted-by":"publisher","first-page":"ofac089","DOI":"10.1093\/ofid\/ofac089","volume":"9","author":"L Tau","year":"2022","unstructured":"Tau L, Turner D, Adler A, et al. SARS-CoV-2 humoral and cellular immune responses of patients with hiv after vaccination with BNT162b2 mRNA COVID-19 vaccine in the Tel-Aviv Medical Center. Open Forum Infect Dis. 2022;9(4):ofac089. https:\/\/doi.org\/10.1093\/ofid\/ofac089.","journal-title":"Open Forum Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07737-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:06:19Z","timestamp":1663769179000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07737-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7737"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07737-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received Yale Human Investigations Committee and Institutional Review Board approval (HIC # 200030266) and written informed consent from subjects was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No relevant financial disclosures, competing interests, or conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"744"}}